GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Inventories, Finished Goods: ₹3,619 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:GLAXO GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
74 GF Score
Price ₹2,420.50
GF Value ₹2,627.22
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GlaxoSmithKline Pharmaceuticals Inventories, Finished Goods?

GlaxoSmithKline Pharmaceuticals NSE:GLAXO -0.73% 74 Inventories, Finished Goods is ₹3,619 Mil as of Mar. 2026. GuruFocus rates NSE:GLAXO with a GF Score™ of 74/100 and a GF Value™ of ₹2,627.22 (Fairly Valued). The stock has 1 warning sign investors should review.

GlaxoSmithKline Pharmaceuticals's quarterly finished goods stayed the same from Sep. 2025 (₹0 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹3,619 Mil).

GlaxoSmithKline Pharmaceuticals's annual finished goods declined from Mar. 2024 (₹4,130 Mil) to Mar. 2025 (₹3,670 Mil) and declined from Mar. 2025 (₹3,670 Mil) to Mar. 2026 (₹3,619 Mil).

GlaxoSmithKline Pharmaceuticals Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline Pharmaceuticals's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals Inventories, Finished Goods Chart

GlaxoSmithKline Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,228.29 3,490.91 4,129.58 3,669.68 3,618.91

GlaxoSmithKline Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,669.68 0.00 0.00 0.00 3,618.91
NSE:GLAXO
74GF Score
GlaxoSmithKline Pharmaceuticals Ltd NSE:GLAXO
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlaxoSmithKline Pharmaceuticals Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of ₹3,619 Mil mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Inventories, Finished Goods of ₹3,619 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors.
Is GlaxoSmithKline Pharmaceuticals' Inventories, Finished Goods too high?
GlaxoSmithKline Pharmaceuticals' current Inventories, Finished Goods is ₹3,619 Mil. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Inventories, Finished Goods compare to LLY and JNJ?
GlaxoSmithKline Pharmaceuticals' Inventories, Finished Goods of ₹3,619 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on GlaxoSmithKline Pharmaceuticals and its competitors. GlaxoSmithKline Pharmaceuticals's current Inventories, Finished Goods is ₹3,619 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,627.22, compared to a current price of ₹2,420.50 — trading 7.9% below its estimated fair value. The current Inventories, Finished Goods is ₹3,619 Mil. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Inventories, Finished Goods is ₹3,619 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?

Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued. The current stock price of ₹2,420.50 is trading 7.9% below its estimated GF Value™ of ₹2,627.22. GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.

Key valuation signals for NSE:GLAXO:

  • Inventories, Finished Goods: ₹3,619 Mil
  • GF Value™: ₹2,627.22 vs. price of ₹2,420.50 (7.9% below fair value)
  • GF Score™: 74/100 with 1 warning sign

No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlaxoSmithKline Pharmaceuticals Business Description

Other Exchanges 500660:India
Address Dr. Annie Besant Road, No. 252, GSK House, Worli, Mumbai, MH, IND, 400030
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
74GF Score

Get the complete analysis for NSE:GLAXO

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,420.50
Price
₹2,627.22
GF Value